Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03446664 · ClinicalTrials.gov registry record · NA
Microburst Vagus Nerve Stimulator (VNS) Therapy Feasibility Study
A NA study of Epilepsies, Partial and Epilepsy, Tonic-Clonic, sponsored by LivaNova.
- Completed
- Registry status
- NA
- Development phase
- 33
- Enrollment target
- 9
- Study locations
NCT03446664 is a NA study of Epilepsies, Partial and Epilepsy, Tonic-Clonic that has completed, run by LivaNova. The registered enrollment target is 33 participants, below the 64-participant average among 4 other Epilepsies, Partial trials with a reported enrollment target (48% lower). The trial reports 9 study locations across 8 states.
The verdict
NCT03446664, a NA study of Epilepsies, Partial and Epilepsy, Tonic-Clonic, has completed, sponsored by LivaNova.
- COMPLETED
- Registry status
- NA
- Development phase
- 33 participants
- Enrollment target
- 9
- Study locations
Study Summary
Evaluate the initial safety and effectiveness of Microburst VNS stimulation in subjects with refractory epilepsy.
Conditions Studied
Interventions
- DEVICE Microburst Stimulation
Study Locations (9)
Illinois
- Rush University - Chicago
- Northwestern University - Evanston
Alabama
- University of Alabama at Birmingham - Birmingham
Colorado
- University of Denver Colorado - Denver
Florida
- Mayo Clinic Florida - Jacksonville
New York
- Weil-Cornell Medical College - Ithaca
North Carolina
- Duke University - Durham
Utah
- University of Utah - Salt Lake City
Other
- Ghent University Hosptial - Ghent
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2018-02-27 |
| Est. Completion | 2021-10-27 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03446664
The ClinicalTrials.gov registry entry for NCT03446664 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 64-participant average among 4 other Epilepsies, Partial trials with a reported enrollment target (48% lower). The listed sponsor is LivaNova, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Epilepsies, Partial appearing as the primary indexed condition, and to 1 intervention - of which Microburst Stimulation is the first listed.
NCT03446664 reports 9 study locations spanning 8 distinct geographic areas - top geographies include Illinois, Alabama, Colorado.
Frequently Asked Questions
What is clinical trial NCT03446664 about?
NCT03446664 is a clinical study titled "Microburst Vagus Nerve Stimulator (VNS) Therapy Feasibility Study". Evaluate the initial safety and effectiveness of Microburst VNS stimulation in subjects with refractory epilepsy.
What is the current status of trial NCT03446664?
This trial is currently completed. It is a NA study. The enrollment target is 33 participants. The study started on 2018-02-27. Estimated completion is 2021-10-27.
What conditions does trial NCT03446664 study?
This clinical trial studies the following conditions: Epilepsies, Partial, Epilepsy, Tonic-Clonic.
What interventions are being tested in trial NCT03446664?
The interventions under investigation include: Microburst Stimulation (DEVICE).
Who is sponsoring clinical trial NCT03446664?
This trial is sponsored by LivaNova, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03446664 being conducted?
This trial has 9 study locations across Alabama, Colorado, Florida, Illinois, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsies, Partial
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Transcranial Direct Current to Treat Epilepsy at Home
ACTIVE NOT RECRUITING · NA
-
Open-Label Extension Study Of Safety And Tolerability Of Pregabalin In Pediatric Patients With Partial-Onset Seizures
COMPLETED · Phase 3
-
Pediatric Epilepsy Study
COMPLETED · Phase 3
-
Safety, Tolerability, and Pharmacokinetic Study of Pregabalin in Pediatric Patients With Partial Onset Seizures
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.